MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Home・Aktien・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Geschlossen

BrancheGesundheitswesen

36.77 0.55

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

36.18

Max

37.14

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 51M
Verkäufe	39M 239M
KGV Branchendurchschnitt	11.426 89.037
EPS	1.08
Gewinnspanne	21.242
Angestellte	268
EBITDA	14M 73M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+21.83% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	399M 2.1B
Vorheriger Eröffnungskurs	36.22
Vorheriger Schlusskurs	36.77

Nachrichtenstimmung

By Acuity

34%

66%

111 / 360 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

29.8 / N/A Unterstützung & Widerstand

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Jan. 2026, 23:49 UTC

Wichtige Markttreiber

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21. Jan. 2026, 21:12 UTC

Wichtige Markttreiber

Automaker Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 21:00 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21. Jan. 2026, 20:29 UTC

Wichtige Markttreiber

Chip Makers Gain After Trump Calls Off European Tariffs

21. Jan. 2026, 20:04 UTC

Wichtige Markttreiber

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21. Jan. 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21. Jan. 2026, 22:39 UTC

Ergebnisse

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21. Jan. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21. Jan. 2026, 21:35 UTC

Akquisitionen, Fusionen, Übernahmen

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21. Jan. 2026, 21:19 UTC

Ergebnisse

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21. Jan. 2026, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Borse Group to Acquire Allfunds for $6.19B

21. Jan. 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21. Jan. 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21. Jan. 2026, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21. Jan. 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21. Jan. 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21. Jan. 2026, 20:26 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21. Jan. 2026, 20:23 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21. Jan. 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21. Jan. 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse Group Agrees to Buy Allfunds

21. Jan. 2026, 20:08 UTC

Ergebnisse

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21. Jan. 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21. Jan. 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21. Jan. 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21. Jan. 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21. Jan. 2026, 19:24 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21. Jan. 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21. Jan. 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

21.83% Vorteil

12-Monats-Prognose

Durchschnitt 43.75 USD 21.83%

Hoch 55 USD

Tief 32 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Harmony Biosciences Holdings Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

29.8 / N/AUnterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

111 / 360 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.